

Navidea Biopharmaceuticals to Present at Sidoti Emerging Growth Conference

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), announces that Rick Gonzalez, President and Chief Executive Officer, will present a corporate overview on Wednesday, September 2, 2015 at 1:30 PM EDT at the <u>Sidoti</u> <u>Emerging Growth Conference</u>, taking place at the Marriott Marquis in Times Square, New York City, NY.

A live webcast of Mr. Gonzalez's presentation can be accessed at the following URL: <u>https://www.webcaster4.com/webcast/page/1223/10233</u>. An archived version of the webcast will be available two hours following the presentation and can be accessed within the Investors' section of the Navidea website at <u>www.navidea.com</u>.

About Navidea

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents. Navidea is developing multiple precision-targeted products and platforms including Manocept[™] and NAV4694 to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Lymphoseek[®] (technetium Tc 99m tilmanocept) injection, Navidea's first commercial product from the Manocept platform, was approved by the FDA in March 2013 and in Europe in November 2014. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and therapeutics, and advancing the Company's pipeline through global partnering and commercialization efforts. For more information, please visit <u>www.navidea.com</u>.

View source version on businesswire.com: <u>http://www.businesswire.com/news/home/20150825005313/en/</u>

Navidea Biopharmaceuticals Investors Tom Baker, 617-532-0624 <u>tbaker@navidea.com</u> or

Media Sharon Correia, 978-655-2686 Associate Director, Corporate Communications

Source: Navidea Biopharmaceuticals, Inc.